Songjiang Ma - Nov 20, 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
President, Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Songjiang Ma
Stock symbol
GYRE
Transactions as of
Nov 20, 2023
Transactions value $
$0
Form type
4
Date filed
11/22/2023, 07:40 PM
Previous filing
Nov 22, 2023
Next filing
Aug 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Award $0 +4.51M $0.00 4.51M Nov 20, 2023 Common Stock 4.51M $0.75 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
F2 These options are vested in full.